CN1234370C - 一种治疗心血管疾病和休克急救的中药注射剂 - Google Patents
一种治疗心血管疾病和休克急救的中药注射剂 Download PDFInfo
- Publication number
- CN1234370C CN1234370C CN 03147020 CN03147020A CN1234370C CN 1234370 C CN1234370 C CN 1234370C CN 03147020 CN03147020 CN 03147020 CN 03147020 A CN03147020 A CN 03147020A CN 1234370 C CN1234370 C CN 1234370C
- Authority
- CN
- China
- Prior art keywords
- shock
- present
- radix ginseng
- chinese medicine
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 230000035939 shock Effects 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 title 1
- 241000208340 Araliaceae Species 0.000 claims abstract description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 41
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 41
- 235000008434 ginseng Nutrition 0.000 claims abstract description 41
- 150000004676 glycans Chemical class 0.000 claims abstract description 34
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 34
- 239000005017 polysaccharide Substances 0.000 claims abstract description 34
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000706 filtrate Substances 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 13
- 238000004321 preservation Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 235000020710 ginseng extract Nutrition 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000003978 infusion fluid Substances 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920003081 Povidone K 30 Polymers 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 229930182490 saponin Natural products 0.000 abstract description 12
- 150000007949 saponins Chemical class 0.000 abstract description 12
- 235000017709 saponins Nutrition 0.000 abstract description 12
- 230000036772 blood pressure Effects 0.000 abstract description 9
- 208000010125 myocardial infarction Diseases 0.000 abstract description 9
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 9
- 230000000747 cardiac effect Effects 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 5
- 230000036513 peripheral conductance Effects 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 230000036770 blood supply Effects 0.000 abstract description 3
- 230000004217 heart function Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 241001448424 Ophiopogon Species 0.000 abstract 3
- 229930195210 Ophiopogon Natural products 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 18
- 239000008176 lyophilized powder Substances 0.000 description 18
- 229940090044 injection Drugs 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930190017 ophiopogonin Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
检测时间 | 组别 | 给药前 | 给药后 | |||||
5min | 30min | 60min | 90min | 120min | 180min | |||
MAP(mmHg) | 模型对照对照组 | 105±13 | 102±18 | 103±16 | 101±15 | 102±16 | 98±12 | 101±14 |
本发明冻干粉低剂量 | 107±10 | 115±11 | 126±11* | 121±15* | 121±13* | 122±12** | 118±15* | |
高剂量 | 102±9 | 113±14 | 128±15** | 125±16** | 125±17** | 126±18** | 125±14** | |
参麦注射液 | 103±11 | 109±13 | 122±10* | 119±13* | 122±14* | 121±12** | 120±17* | |
HR(次/min) | 模型对照对照组 | 135±27 | 132±25 | 135±26 | 132±21 | 128±29 | 128±27 | 129±30 |
本发明冻干粉低剂量 | 143±31 | 139±27 | 134±25 | 132±28 | 135±29 | 133±31 | 136±27 | |
高剂量 | 133±24 | 128±21 | 124±24 | 125±21 | 123±26 | 124±22 | 125±21 | |
参麦注射液 | 140±24 | 135±19 | 132±23 | 130±19 | 129±6 | 130±28 | 133±25 | |
CO(L/min) | 模型对照对照组 | 1.10±0.31 | 1.07±0.30 | 1.05±0.32 | 1.06±0.31 | 1.04±0.29 | 1.05±0.30 | 1.06±0.33 |
本发明冻干低剂量 | 1.07±0.17 | 1.10±0.18 | 1.23±0.20 | 1.26±0.22 | 1.25±0.24 | 1.24±0.19 | 1.22±0.23 | |
高剂量 | 1.04±0.24 | 1.09±0.28 | 1.25±0.25 | 1.33±0.27* | 1.32±0.28* | 1.30±0.24* | 1.29±0.27 | |
参麦注射液 | 1.07±0.19 | 1.12±0.22 | 1.22±0.23 | 1.30±0.20* | 1.29±0.21* | 1.29±0.21* | 1.25±0.21 | |
TPVR(mmHg.S/L) | 模型对照对照组 | 883.5±132.2 | 892.2±152.2 | 875.6±121.5 | 884.2±136.8 | 846.6±165.1 | 854.6±141.8 | 861.9±154.2 |
本发明冻干粉低剂量 | 899.7±1 75.6 | 936.2±241.2 | 919.3±218.1 | 889.3±208.6 | 874.6±228.6 | 886.6±253.2 | 873.5±198.2 | |
高剂量 | 884.5±109.5 | 926.3±136.5 | 916.2±108.4 | 952.2±148.6 | 924.5±152.8 | 902.5±95.4 | 875.5±110.7 | |
参麦注射液 | 872.2±86.9 | 879.6±110.2 | 886.2±121.3 | 887.0±1 38.3 | 871.6±154.2 | 828.6±12 8.5 | 847.9±97.8 |
检测指标 | 组别 | 给药前 | 开始给药后 | |||||
5min | 30min | 60min | 90min | 120min | 180min | |||
N-ST | 模型对照 | 10.11±0.85 | 10.55±0.72 | 11.12±0.82 | 11.23±0.72 | 11.66±0.89 | 11.44±0.90 | 10.62±1.37 |
本发明冻干粉低剂量 | 9.95±1.02 | 9.87±0.98 | 8.76±0.85* | 9.31±1.24* | 8.21±0.94* | 8.16±1.19* | 87.12±1.18* | |
高剂量 | 10.89±1.79 | 7.25±2.17 | 4.31±3.25** | 4.12±1.56** | 3.68±1.91** | 4.65±2.65** | 4.83±1.26** | |
参麦注射液 | 11.06±1.29 | 8.21±1.25 | 4.67±1.87** | 3.23±2.18** | 3.12±2.54** | 3.46±2.37** | 3.75+3.62** | |
∑-ST | 模型组 | 4.07±0.39 | 4.66±0.27 | 4.79±0.74 | 4.62±0.97 | 4.57±1.21 | 4.48±0.78 | 4.02±1.11 |
本发明冻干粉低剂量 | 3.06±0.88 | 2.84±0.84 | 2.77±1.12* | 2.47±1.02* | 2.96±1.34** | 2.85±1.03** | 3.12±1.21 | |
高剂量 | 3.05±0.96 | 2.21±0.88 | 1.44±0.98** | 1.39±0.74** | 1.54±0.72** | 1.57±0.60** | 1.77±0.97** | |
参麦注射液 | 3.05±0.67 | 2.32±1.04 | 1.67±1.15** | 1.52±0.90** | 1.68±0.86** | 1.77±0.54** | 1.93±0.78** |
组别 | 心肌梗死范围(%) | LDH | CPK | ||
给药前 | 给药后 | 给药前 | 给药后 | ||
模型对照组 | 23.21±5.21 | 211.2±51.21 | 352.1±68.98 | 598.5±208.75 | 964.6±281.2 |
本发明冻粉低剂量 | 16.18±6.28* | 235.8±50.14 | 251.1±63.72** | 624.9±263.84 | 685.6±302.1** |
中剂量 | 12.46±7.86** | 224.9±48.76 | 219.5±40.82** | 592.5±251.71 | 616.3±232.5** |
参麦注射液 | 14.82±6.82* | 219.3±44.72 | 230.7±53.91** | 619.8±198.76 | 676.9±263.2** |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03147020 CN1234370C (zh) | 2003-09-30 | 2003-09-30 | 一种治疗心血管疾病和休克急救的中药注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03147020 CN1234370C (zh) | 2003-09-30 | 2003-09-30 | 一种治疗心血管疾病和休克急救的中药注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1528336A CN1528336A (zh) | 2004-09-15 |
CN1234370C true CN1234370C (zh) | 2006-01-04 |
Family
ID=34286734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03147020 Expired - Fee Related CN1234370C (zh) | 2003-09-30 | 2003-09-30 | 一种治疗心血管疾病和休克急救的中药注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1234370C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101593618B1 (ko) * | 2009-05-26 | 2016-02-15 | (주)아모레퍼시픽 | 사포닌의 생체 이용률 증진 조성물 |
CN104623262B (zh) * | 2013-11-12 | 2017-12-19 | 华润三九(雅安)药业有限公司 | 一种参麦注射液及其制备方法 |
CN105267619B (zh) * | 2014-06-07 | 2018-05-01 | 兰州大学 | 一种抑制ras原癌基因过表达的抗肿瘤中药复方提取物 |
-
2003
- 2003-09-30 CN CN 03147020 patent/CN1234370C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1528336A (zh) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101088521B (zh) | 一种黄芪药物制剂及其制备方法 | |
CN101085000A (zh) | 一种含丹酚酸b的复方丹参冻干粉针剂及其制备方法 | |
CN102048821B (zh) | 一种冠心宁药物制剂的制备方法 | |
CN103837609A (zh) | 一种生脉注射液及其制备方法 | |
CN1234370C (zh) | 一种治疗心血管疾病和休克急救的中药注射剂 | |
CN1981849B (zh) | 一种黄芪生脉注射制剂的制备方法及其应用 | |
CN1895307A (zh) | 一种治疗心脑血管疾病的中药提取物和其制备方法及其用途 | |
CN100377731C (zh) | 一种中药及其制备方法和用途 | |
CN1899509A (zh) | 一种益气复脉的中药注射剂及制备方法 | |
CN100536890C (zh) | 一种抗心律失常中药组合物及其制备方法 | |
CN101085001A (zh) | 一种含丹参素的复方丹参冻干粉针剂及其制备方法 | |
CN1468860A (zh) | 刺五加总皂苷提取物及其药物组合物 | |
CN1081465C (zh) | 一种治疗冠心病心绞痛的红景天注射剂的制备方法 | |
CN1244333C (zh) | 一种大株红景天粉针剂及其制备方法 | |
CN101199568A (zh) | 一种治疗心血管疾病的药物组合物及其制备方法 | |
CN1229127C (zh) | 一种防治高血压的药物组合物及其质量控制方法和用途 | |
CN102100731B (zh) | 黄芪总苷提取物新用途及其制备方法 | |
CN1425379A (zh) | 一种治疗心脑血管疾病的中药有效部位复方制剂及其制备方法 | |
CN1689593A (zh) | 一种注射用参附粉针剂的制备方法 | |
CN102319401A (zh) | 一种用于益气活血、健脾通络的中药组合物及其制备方法 | |
CN1283482A (zh) | 一种治心血管病的药物组合物及其制备方法 | |
CN1883654A (zh) | 黄芪生脉注射制剂及制备工艺 | |
CN100484543C (zh) | 一种治疗肝炎的药物组合物及其制备方法和用途 | |
CN1557403A (zh) | 一种治疗心脑血管疾病的药物及其制备方法 | |
CN1259934C (zh) | 一种用于治疗心血管疾病的山楂叶注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHENG FEIXIONG Free format text: FORMER OWNER: GUANGZHOU OUHUA PHARMACEUTICAL BIOTECHNOLOGY CO.LTD. Effective date: 20080704 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080704 Address after: Room 15, block 506, Lake District, Gulou District, Fujian, Fuzhou Patentee after: Zheng Feixiong Address before: Guangdong province Guangzhou city forest and Road No. 150, Room 802, Tianyu Garden Plaza Accord Patentee before: Ouhua Medicine Biotechnology Co., Ltd., Guangzhou |
|
ASS | Succession or assignment of patent right |
Owner name: FUZHOU KERRY PHARMACEUTICAL CONSULTING CO., LTD. Free format text: FORMER OWNER: ZHENG FEIXIONG Effective date: 20091016 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091016 Address after: North Bank of the Union Hotel, 136 drum Road, Gulou District, Fujian, Fuzhou Province, five Patentee after: Fuzhou Kerry Medical Consulting Co., Ltd. Address before: Room 15, block 506, Lake District, Gulou District, Fujian, Fuzhou Patentee before: Zheng Feixiong |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20180930 |
|
CF01 | Termination of patent right due to non-payment of annual fee |